This guidance will fully update the following:
|
Status
|
In progress
|
| Process |
MTA
|
|
Topic area
|
|
Provisional Schedule
| Committee meeting: 4 |
26 July 2017 |
| Expected publication |
11 October 2017 |
Project Team
Email enquiries
Consultees
| Companies sponsors |
Accord Healthcare (confidentiality agreement not signed, not participating) |
| |
Actavis (confidentiality agreement not signed, not participating) |
| |
Arrow Pharmaceuticals (confidentiality agreement not signed, not participating) |
| |
Astellas Pharma |
| |
Bristol-Myers Squibb |
| |
Dexcel Pharma (confidentiality agreement not signed, not participating) |
| |
Dr Reddy's Laboratories (confidentiality agreement not signed, not participating) |
| |
Mylan (confidentiality agreement not signed, not participating) |
| |
Novartis Pharmaceuticals |
| |
Pfizer (confidentiality agreement not signed, not participating) |
| |
Roche Products |
| |
Sandoz |
| |
Sanofi |
| |
Teva |
| |
Wockhardt (confidentiality agreement not signed, not participating) |
| |
Zentiva (confidentiality agreement not signed, not participating) |
| Others |
Department of Health |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
British Kidney Patient Association |
| |
Kidney Research UK |
| |
National Kidney Federation |
| Professional groups |
British Association of Paediatric Nephrology |
| |
British Transplantation Society |
| |
ESPRIT |
| |
Royal College of Paediatric and Child Health |
| |
Royal College of Physicians |
Commentators
| Comparator companies |
Actavis (confidentiality agreement not signed, not participating) |
| |
Arrow Generics (confidentiality agreement not signed, not participating) |
| |
Aspen Europe (confidentiality agreement not signed, not participating) |
| |
Beacon Pharmaceuticals(confidentiality agreement not signed, not participating) |
| |
Dexcel Pharma (confidentiality agreement not signed, not participating) |
| |
Intrapharm Laboratories(confidentiality agreement not signed, not participating) |
| |
LPC Medical (confidentiality agreement not signed, not participating) |
| |
Metwest Pharmaceuticals (confidentiality agreement not signed, not participating) |
| |
Mylan (confidentiality agreement not signed, not participating) |
| |
Novartis Pharmaceuticals |
| |
Pfizer (confidentiality agreement not signed, not participating) |
| |
Sandoz |
| |
Teva |
| |
Wockhardt (confidentiality agreement not signed, not participating) |
| |
Zentiva (confidentiality agreement not signed, not participating) |
| General commentators |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Cochrane Renal Group |
|
Date
|
Update
|
|
28 April 2017 - 22 May 2017
|
Appraisal consultation |
|
29 March 2017
|
Committee meeting: 3 |
|
01 June 2016
|
Appeal decision |
|
30 March 2016
|
Appeal |
|
16 December 2015 - 19 January 2016
|
Final appraisal determination |
|
04 November 2015
|
Committee meeting: 2 |
|
07 July 2015
|
Committee meeting: 1 |
|
27 November 2014
|
Due to the size and complexity of this appraisal the Assessment Group, Peninsula Technology Assessment Group (PenTAG), have requested further time to prepare the a review of the clinical and cost effectiveness of the technology. This request has been considered and as a consequence the first committee meeting for this topic has been rescheduled to 7 July 2015. |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance